{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-001482","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.485662+00:00","generated_at":"2026-06-08T03:14:20.038334+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivani Medical Q3 net loss $6.8M; adds NPM-115 for weight management","bullets":["Net loss of $6.8M in Q3 2023 vs net income of $1.4M in Q3 2022, driven by prior-year bargain purchase gain.","Cash and equivalents $26.2M at Sept 30, 2023; expected to fund operations into early 2025.","Announced NPM-115 (high-dose exenatide implant) for chronic weight management in obese/overweight patients.","FDA clinical hold on NPM-119 FIH study due to CMC requests; also planning FIH study in Australia.","R&D expense $4.4M (+15% YoY); G&A expense $2.7M (+71% YoY) due to merger-related costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-001482","json":"https://secwatch.observer/filing/0001753926-23-001482.json","markdown":"https://secwatch.observer/filing/0001753926-23-001482.md","text":"https://secwatch.observer/filing/0001753926-23-001482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623001482/0001753926-23-001482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623001482/g083854_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:14:20.038334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6c62e899b1a1824cbc96fa23449ab92053fc6e6","claim":"Vivani Medical, Inc. reported financial results for third quarter of 2023.","evidence_excerpt":"today reported financial results for the third quarter of 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623001482/0001753926-23-001482-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}